Novartis Could See Five Gleevec Approvals In Next Year
This article was originally published in The Pink Sheet Daily
The firm has applied for five additional indications of imatinib since December.
You may also be interested in...
Simultaneous approvals add a solid tumor cancer and four blood disorders to the targeted oncologic’s labeling, for a total of seven indications in five years.
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.